Healios K.K. researches and develops iPSC Regenerative Medicine and Compound Drugs. The company researches for the development of treatment for Age-Related Macular Degeneration.

Announcement Of Changes In Management And Organization

Development And Application Policy For Hlcm051 (Ards And Ischemic Stroke Treatment)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

HEALIOS KK (4593 JP)

Announcement Of Changes In Management And Organization

Development And Application Policy For Hlcm051 (Ards And Ischemic Stroke Treatment)

Fy2025 Q3 Financial Results (Material)

Notice Regarding The Termination Of The Business And Capital Alliance Agreement With Nikon Corporation

Notice Of Joint Research Agreement With Kyushu University On Immuno-Cell Therapy For Brain Tumors Using Healios’ Gene-Edited Car-Enk Cells

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)